Logo

Lineage Signs an Exclusive WW Agreement with Genentech to Develop and Commercialize OpRegen RPE Cell Therapy for the Treatment of Ocular Disorders

Share this

Lineage Signs an Exclusive WW Agreement with Genentech to Develop and Commercialize OpRegen RPE Cell Therapy for the Treatment of Ocular Disorders

Shots:

  • Lineage to receive a $50M up front and is eligible to receive ~$620M in additional development, approval, and sales milestone along with royalties
  • The collaboration will combine Lineage’s cell therapy technology with Genentech’s ophthalmology expertise and capabilities to advance the OpRegen program for serious ocular disorders including dry AMD
  • Lineage will be responsible to complete the activities related to the ongoing clinical study and perform manufacturing activities. Genentech will lead the clinical development and commercialization of Lineage’s OpRegen program which is currently being evaluated in a P-I/IIa dose-escalation study for advanced dry AMD with GA

Ref: Businesswire | Image: Lineage

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions